多发性骨髓瘤患者COVID-19结局相关临床特征:国际骨髓瘤学会数据集首批结果
该回顾性研究由国际骨髓瘤学会收集650例浆细胞疾病患者的COVID-19基线特征与结局数据,以了解疫情期间骨髓瘤患者面临的初始挑战。多因素分析显示年龄、高危MM、肾脏疾病及MM控制不佳是COVID-19不良结局的独立预测因素。
要点
- 高龄、高危MM、肾脏疾病及MM控制不佳是独立不良预后因素。
- 移植史及抗MM治疗与COVID-19结局无关,应兼顾感染防控与疾病控制。
核心结论
- 住院MM患者COVID-19死亡率高,年龄、高危MM、肾脏疾病及MM控制不佳为独立不良预后因素。
研究设计与样本
- 国际骨髓瘤学会收集的回顾性研究,共650例浆细胞疾病患者,分析针对住院MM患者。
主要发现
- 住院患者中位年龄69岁,96%为MM,36%为2019-2020年近期诊断,54%接受一线治疗。
- 单因素分析中年龄、ISS3期、高危疾病、肾脏疾病、MM控制不佳及≥1种合并症与更高死亡率相关。
- 移植史(包括COVID-19诊断前一年内)及其他抗MM治疗与结局无关。
- 多因素分析仅年龄、高危MM、肾脏疾病及MM控制不佳为不良结局的独立预测因素。
临床怎么用
- COVID-19时代MM管理需审慎评估患者及疾病相关因素,在降低感染风险的同时通过适当治疗不损害疾病控制。
局限性
- 回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The primary cause of morbidity and mortality in patients with multiple myeloma (MM) is an infection. Therefore, there is great concern about susceptibility to the outcome of COVID-19-infected patients with MM. This retrospective study describes the baseline characteristics and outcome data of COVID-19 infection in 650 patients with plasma cell disorders, collected by the International Myeloma Society to understand the initial challenges faced by myeloma patients during the COVID-19 pandemic. Analyses were performed for hospitalized MM patients. Among hospitalized patients, the median age was 69 years, and nearly all patients (96%) had MM. Approximately 36% were recently diagnosed (2019-2020), and 54% of patients were receiving first-line therapy. Thirty-three percent of patients have died, with significant geographic variability, ranging from 27% to 57% of hospitalized patients. Univariate analysis identified age, International Staging System stage 3 (ISS3), high-risk disease, renal disease, suboptimal myeloma control (active or progressive disease), and 1 or more comorbidities as risk factors for higher rates of death. Neither history of transplant, including within a year of COVID-19 diagnosis, nor other anti-MM treatments were associated with outcomes. Multivariate analysis found that only age, high-risk MM, renal disease, and suboptimal MM control remained independent predictors of adverse outcome with COVID-19 infection. The management of MM in the era of COVID-19 requires careful consideration of patient- and disease-related factors to decrease the risk of acquiring COVID-19 infection, while not compromising disease control through appropriate MM treatment. This study provides initial data to develop recommendations for the management of MM patients with COVID-19 infection.
引用
- Chari A, Samur MK, Martinez-Lopez J, et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020. PMID: 33367546. doi:10.1182/blood.2020008150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。